Intrexon | XON - Selling And Administration Expenses


Intrexon reported $10.31M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Agenus USD 6.21M 4.34M Mar/2026
Alaunos Therapeutics USD 424K 23K Jun/2026
Amgen USD 1.68B 40M Sep/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Incyte USD 364.27M 12.54M Sep/2026
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Ligand Pharmaceuticals USD 72.62M 43.49M Sep/2026
MacroGenics USD 7.9M 1.81M Jun/2026
MannKind USD 61.41M 3.11M Sep/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Thermo Fisher Scientific USD 1.86B 46M Sep/2026
Veracyte USD 57.95M 2.25M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026